FMR LLC lowered its position in shares of Establishment Labs Holdings Inc (NASDAQ:ESTA) by 0.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 636,071 shares of the company’s stock after selling 1,208 shares during the quarter. FMR LLC owned approximately 3.10% of Establishment Labs worth $17,441,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Fosun International Ltd bought a new stake in shares of Establishment Labs in the 3rd quarter valued at approximately $182,000. BlackRock Inc. purchased a new stake in shares of Establishment Labs in the third quarter worth approximately $5,088,000. Granite Point Capital Management L.P. purchased a new stake in shares of Establishment Labs in the third quarter worth approximately $545,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Establishment Labs in the third quarter worth approximately $954,000. Finally, Kornitzer Capital Management Inc. KS purchased a new stake in shares of Establishment Labs in the third quarter worth approximately $361,000. Institutional investors and hedge funds own 23.14% of the company’s stock.
Separately, BTIG Research restated a “buy” rating and set a $40.00 price objective on shares of Establishment Labs in a report on Monday, March 25th.
ESTA traded up $0.84 during trading on Friday, hitting $22.01. 198,942 shares of the stock were exchanged, compared to its average volume of 98,489. The company has a market capitalization of $431.64 million and a P/E ratio of -19.65. Establishment Labs Holdings Inc has a 1 year low of $20.05 and a 1 year high of $30.70. The company has a quick ratio of 4.54, a current ratio of 6.05 and a debt-to-equity ratio of 0.32.
Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.51) EPS for the quarter. The firm had revenue of $16.40 million for the quarter, compared to analysts’ expectations of $14.70 million. Establishment Labs had a negative return on equity of 90.07% and a negative net margin of 34.47%. Equities analysts anticipate that Establishment Labs Holdings Inc will post -1.58 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Modern Readers and is owned by of Modern Readers. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.modernreaders.com/news/2019/04/14/fmr-llc-lowers-position-in-establishment-labs-holdings-inc-esta.html.
Establishment Labs Company Profile
Establishment Labs Holdings Inc, a medical technology company, designs, develops, manufactures, and markets medical devices for aesthetic plastic surgery, reconstructive plastic surgery, and aesthetic dermatology. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name.
Further Reading: How a Put Option Works
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.